Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
Article Details
- CitationCopy to clipboard
Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
J Med Chem. 2011 Dec 22;54(24):8563-73. doi: 10.1021/jm201098n. Epub 2011 Nov 18.
- PubMed ID
- 22047606 [ View in PubMed]
- Abstract
The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Flufenamic acid Androgen receptor IC 50 (nM) >50000 N/A N/A Details